An independent two-stage DCF analysis by a frontier AI model.
The Cigna Group operates not just as a traditional health insurer, but as a deeply integrated healthcare services powerhouse through its Evernorth division. The market frequently fixates on the political headlines surrounding Pharmacy Benefit Managers (PBMs), temporarily depressing the valuation and ignoring the immense cash flow this business generates.
At its current valuation, the market is pricing in near-zero growth. However, Cigna's scale allows it to wring out efficiencies and negotiate aggressively across the healthcare supply chain. Combined with a management team committed to massive share repurchase programs and a growing dividend, the company offers a highly compelling margin of safety for long-term investors willing to weather short-term regulatory noise.
A 6.0% growth rate acknowledges Cigna's robust free cash flow generation from its massive scale and the faster-growing Evernorth segment, balanced against modest growth in its mature commercial insurance business.
An 8.0% discount rate reflects the company's strong, predictable cash flows and defensive characteristics in the healthcare sector, slightly elevated to account for ongoing legislative and regulatory risks associated with Pharmacy Benefit Managers (PBMs).
2.0% is a conservative terminal rate, aligning with long-term inflation targets and historical GDP growth, recognizing that outsized growth becomes increasingly difficult at its massive scale.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $798.65 | $665.54 | $570.46 | $499.16 | $443.69 |
| 1.5% | $887.39 | $726.04 | $614.34 | $532.43 | $469.79 |
| 2.0% | $998.31 | $798.65 | $665.54 | $570.46 | $499.16 |
| 2.5% | $1,140.93 | $887.39 | $726.04 | $614.34 | $532.43 |
| 3.0% | $1,331.08 | $998.31 | $798.65 | $665.54 | $570.46 |
■ Undervalued vs current price ■ Overvalued vs current price
Gemini projects that while traditional insurance enrollment growth may be sluggish, the Evernorth health services segment—particularly specialty pharmacy—will continue to drive mid-single-digit free cash flow growth.
An 8.0% discount rate was selected. This balances the highly defensive nature of the healthcare sector and Cigna's reliable cash generation against the tangible political and regulatory risks facing the PBM industry.
No. This analysis is a demonstration of AI reasoning based on a specific set of inputs and rigid formulas. It is not financial advice. AI models cannot predict regulatory actions, geopolitical shifts, or black swan economic events.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.